Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
Purpose: To evaluate the potential utility of histone deacetylase inhibitors (HDACi) for treatment of retinoblastoma (RB). Experimental Design: Growth-inhibitory effects of HDACi [trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or MS-275] were assessed in human and transgenic murine RB...
Saved in:
Published in | Clinical cancer research Vol. 14; no. 10; pp. 3113 - 3123 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research
15.05.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: To evaluate the potential utility of histone deacetylase inhibitors (HDACi) for treatment of retinoblastoma (RB).
Experimental Design: Growth-inhibitory effects of HDACi [trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or MS-275] were assessed
in human and transgenic murine RB cells. Effects of TSA and MS-275 were also assessed in combination with standard therapeutic
agents for RB. Proapoptotic effects of MS-275 and TSA were evaluated by caspase-3/7 activity, Annexin V translocation, and/or
Bim expression analyses. Effects of MS-275 on cell cycle distribution and reactive oxygen species levels were determined by flow
cytometry. Retinal tissue morphology was evaluated in mice after local administration of MS-275. Analysis of retinal acetyl-histone
levels was used to assess MS-275 delivery after systemic administration. Therapeutic effects of MS-275 were determined in
transgenic mouse and rat ocular xenograft models of RB after i.p. injection of 20 mg/kg every other day for 21 or 13 days,
respectively.
Results: TSA, SAHA, and MS-275 dose dependently reduced RB cell survival. TSA and MS-275 showed additive growth-inhibitory effects
in combination with carboplatin, etoposide, or vincristine. TSA and MS-275 increased caspase-3/7 activity. MS-275 increased
Annexin V membrane translocation and induced G 1 arrest. Cytotoxicity of MS-275 was dependent on increased reactive oxygen species levels and was reversed by antioxidant
pretreatment. Intraocular administration of 1 μL of 10 μmol/L MS-275 did not alter ocular tissue morphology. Increased acetyl-histone
levels confirmed MS-275 delivery to retinal tissue after systemic administration. MS-275 significantly reduced tumor burden
in both mouse and rat models of RB.
Conclusions: HDACi should be considered for clinical trials in children with RB. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-07-4836 |